Eagle Pharmaceuticals
(OTC) EGRX
Eagle Pharmaceuticals Financials at a Glance
Market Cap
$4.43M
Revenue (TTM)
$257.55M
Net Income (TTM)
$15.57M
EPS (TTM)
$0.00
P/E Ratio
0.00
Dividend
$0.00
Beta (Volatility)
-20.61 (Low)
Dividend
$0.00
Beta (Volatility)
-20.61 (Low)
Price
$0.34
Volume
104
Open
$0.34
Price
$0.34
Volume
104
Open
$0.34
Previous Close
$0.34
Daily Range
$0.34 - $0.34
52-Week Range
$0.00 - $3.87
Dividend
$0.00
Beta (Volatility)
-20.61 (Low)
Price
$0.34
Volume
104
Open
$0.34
Previous Close
$0.34
Daily Range
$0.34 - $0.34
52-Week Range
$0.00 - $3.87
EGRX News
3 Top Biotech Stocks to Buy in 2017
The Best Biotech Stocks in 2015
EGRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Eagle Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
135
CEO
Scott L. Tarriff, MBA
Website
www.eagleus.comHeadquarters
Woodcliff Lake, NJ 07677, US
EGRX Financials
Key Financial Metrics (TTM)
Gross Margin
70%
Operating Margin
26%
Net Income Margin
11%
Return on Equity
0%
Return on Capital
27%
Return on Assets
9%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$4.43M
Shares Outstanding
12.99M
Volume
104
Short Interest
0.00%
Avg. Volume
2.62K
Financials (TTM)
Gross Profit
$221.67M
Operating Income
$80.96M
EBITDA
$77.50M
Operating Cash Flow
$30.80M
Capital Expenditure
$0.00
Free Cash Flow
$30.80M
Cash & ST Invst.
$55.32M
Total Debt
$67.79M
Eagle Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$64.65M
-12.8%
Gross Profit
$47.79M
-5.3%
Gross Margin
73.92%
N/A
Market Cap
$4.43M
N/A
Market Cap/Employee
$33.06K
N/A
Employees
134
N/A
Net Income
$5.16M
+154.6%
EBITDA
$16.33M
+641.1%
Quarterly Fundamentals
Net Cash
$56.26M
-230.3%
Accounts Receivable
$116.28M
+33.0%
Inventory
$42.48M
-26.4%
Long Term Debt
$61.90M
+104.5%
Short Term Debt
$9.72M
-58.3%
Return on Assets
8.78%
N/A
Return on Invested Capital
27.44%
N/A
Free Cash Flow
$132.00K
-100.3%
Operating Cash Flow
$126.00K
-100.3%